- Home
- ALNY vs FIS Comparison
ALNY vs FIS Comparison
Compare ALNY & FIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- FIS
- Stock Information
- Founded
- ALNY 2002
- FIS 1968
- Country
- ALNY United States
- FIS United States
- Employees
- ALNY N/A
- FIS N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- FIS Business Services
- Sector
- ALNY Health Care
- FIS Consumer Discretionary
- Exchange
- ALNY Nasdaq
- FIS Nasdaq
- Market Cap
- ALNY 40.4B
- FIS 42.3B
- IPO Year
- ALNY 2004
- FIS N/A
- Fundamental
- Price
- ALNY $320.87
- FIS $79.80
- Analyst Decision
- ALNY Strong Buy
- FIS Buy
- Analyst Count
- ALNY 24
- FIS 20
- Target Price
- ALNY $341.91
- FIS $89.67
- AVG Volume (30 Days)
- ALNY 863.4K
- FIS 2.8M
- Earning Date
- ALNY 07-31-2025
- FIS 08-05-2025
- Dividend Yield
- ALNY N/A
- FIS 2.00%
- EPS Growth
- ALNY N/A
- FIS N/A
- EPS
- ALNY N/A
- FIS 1.52
- Revenue
- ALNY $2,348,099,000.00
- FIS $10,191,000,000.00
- Revenue This Year
- ALNY $30.77
- FIS $4.49
- Revenue Next Year
- ALNY $30.51
- FIS $4.47
- P/E Ratio
- ALNY N/A
- FIS $52.58
- Revenue Growth
- ALNY 17.21
- FIS 2.92
- 52 Week Low
- ALNY $205.87
- FIS $66.51
- 52 Week High
- ALNY $333.70
- FIS $91.98
- Technical
- Relative Strength Index (RSI)
- ALNY 57.52
- FIS 47.77
- Support Level
- ALNY $314.10
- FIS $80.58
- Resistance Level
- ALNY $328.99
- FIS $82.02
- Average True Range (ATR)
- ALNY 9.40
- FIS 1.33
- MACD
- ALNY -1.23
- FIS -0.21
- Stochastic Oscillator
- ALNY 52.48
- FIS 20.29
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About FIS Fidelity National Information Services Inc.
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.